| Formulary Chapter 13: Skin - Full Chapter
|
| Notes: |
Please note: Silk garments are non-formulary. |
|
| Details... |
| 13.01 |
Management of skin conditions |
|
|
Octenisan®
|
Formulary
|
For MRSA skin decolonisation , if chlorhexidine sensitivity is a problem
|
|
|
|
|
| 13.01.02 |
Suitable quantities for prescribing |
|
|
| 13.01.02 |
Spray emollients |
|
|
| 13.01.03 |
Excipients and sensitisation |
|
|
| 13.02 |
Emollient and barrier preparations |
|
|
|
|
Aveeno cream®
|
Formulary
|
£££- Paediatrics only
 £££- Recommended by specialist for oncology use only.
|
|
|
Cetraben emollient cream®
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
 BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
 Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
DoubleBase Gel ®
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Emulsifying Ointment BP
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Epaderm® ointment
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Epimax ® cream
|
Formulary
|
|
|
|
Hydromol Cream®
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Hydromol ointment ®
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Hydrous ointment BP
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Liquid and White Soft Paraffin Ointment (50:50)
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
White Soft Paraffin BP
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
ZeroAQS-®
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Zerobase®
|
Formulary
|
|
|
|
Zerocream®
|
Formulary
|
|
|
|
Zeroderm Ointment®
|
Formulary
|
|
|
|
Zeroguent®
|
Formulary
|
|
|
|
|
|
| 13.02.01 |
Preparations containing urea |
|
|
Aquadrate®
|
Formulary
|
Contains 10% urea
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Balneum® Plus cream
|
Formulary
|
- urea 5%, lauromacrogols 3%
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Dermatonics Once Heel Balm®
|
Formulary
|
specialist recommendation for epidermolysis bullosa
|
|
|
Eucerin® Intensive lotion 10%urea
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
| 13.02.01 |
With antimicrobials |
|
|
Dermol 500 lotion ®
|
Formulary
|
short term use only
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
| 13.02.01.01 |
Emollient bath and shower preparations |
|
|
Balneum Plus ®Bath Additive
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Hydromol® bath and shower
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
ZeroAQS®cream
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
| 13.02.01.01 |
With antimicrobials |
|
|
Dermol 600®
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
| 13.02.02 |
Barrier preparations |
|
|
Conotrane®
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
Link to wound management section of formulary
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Metanium®
|
Formulary
|
- specialist recommendation
Over the counter preparation suitable for self-care/purchase if appropriate
|
Link to wound management section of the formulary
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Sudocrem®
|
Formulary
|
- avoid use with continence pads
Over the counter preparation suitable for self-care/purchase if appropriate
|
Link to wound management section of the formulary
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Zinc and Castor Oil Ointment BP
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
Link to wound management section of the formulary
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
| 13.03 |
Topical local anaesthetics and antipruritics |
|
|
Calamine Aqueous Cream
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Calamine Lotion
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Crotamiton (Eurax®)
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Doxepin Hcl cream (Xepin ®)
|
Formulary
|
|
Doxepin Hcl RICaD
|
Menthol in Aqueous cream
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
| 13.04 |
Topical corticosteriods. |
|
|
Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 3% (Diprosalic Ointment®)
|
Formulary
|
Potency: potent
|
|
|
Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 3% (Diprosalic Scalp Application®)
|
Formulary
|
Potency: potent
|
|
|
Betamethasone (as Valerate) 0.025% (Betnovate-RD Cream®)
|
Formulary
|
Potency: Moderate
|
|
|
Betamethasone (as Valerate) 0.025% (Betnovate-RD Ointment®)
|
Formulary
|
Potency: Moderate
|
|
|
Betamethasone (as Valerate) 0.1% (Betnovate ®)
|
Formulary
|
Potency: Potent
Cream
Ointment
Scalp application
|
|
|
Betamethasone (as Valerate) 0.1% with Fucidic Acid 2% (Fucibet cream®)
|
Formulary
|
Potency: potent
|
|
|
Betamethasone Dipropionate 0.064% with Clotrimazole 1% (Lotriderm®)
|
Formulary
|
Potency: potent
|
|
|
Clobetasol Propionate 0.05% (Dermovate®)
|
Formulary
|
Potency: very potent
Cream
Ointment
Scalp application
|
|
|
Clobetasone Butyrate 0.05% cream (Eumovate®)
|
Formulary
|
Potency: moderate
|
|
|
Clobetasone Butyrate 0.05% ointment (Eumovate®)
|
Formulary
|
Potency: moderate
|
|
|
Diflucortolone Valerate 0.3% oily cream
|
Formulary
|
Potency: very potent
|
|
|
Flucinolone Acetonide 0.0025% (Synalar 1 in 10 Dilution®)
|
Formulary
|
Paeds use only
Potency :Mild
February 2017: aware of unavailability, use alternative mild potency preparation.
|
|
|
Flucinolone Acetonide 0.025% (Synalar Gel®)
|
Formulary
|
£££
Potency:Potent
|
|
|
Fludroxycortide 7.5cm x 200cm tape (previously known as Haelan®)
|
Formulary
|
££
Potency: moderate
|
|
|
fluocinolone acetonide 0.025% with clioquinol 3% (Synalar C®)
|
Formulary
|
Potency: potent
Cream
Ointment
|
|
|
Hydrocortisone
|
Formulary
|
Potency: mild
Hydrocortisone 0.5% cream & ointment
Hydrocortisone 1% cream & ointment
|
|
|
Hydrocortisone 0.25% Crotamiton 10% (Eurax-Hydrocortisone®)
|
Formulary
|
Potency: mild
Use post scabies once infection has cleared but itch remains present
|
|
|
Hydrocortisone 0.5% ,chlorhexidine HCl 1% & nystatin (Nystaform-HC®)
|
Formulary
|
Potency: mild
Cream
Ointment
Paeds use only
Replacement for discontinued Vioform HC
|
|
|
Hydrocortisone 1% with Clotrimazole 1% (Canesten HC®)
|
Formulary
|
Potency: mild
|
|
|
Hydrocortisone 1% with Miconazole Nitrate 2% (Daktacort Cream®)
|
Formulary
|
Potency: mild
|
|
|
Hydrocortisone Acetate 1% with Fusidic Acid 2% (Fucidin H Cream®)
|
Formulary
|
Potency: mild
|
|
|
Hydrocortisone Butyrate (Locoid ®)
|
Formulary
|
Potency: potent
Cream
Lipocream
Ointment
Scalp lotion
|
|
|
Mometasone Furoate 0.1%
|
Formulary
|
Potency: potent
Cream
Ointment
Scalp lotion ££
|
|
|
Timodine®
|
Formulary
|
Potency: mild
|
|
|
Trimovate®
|
Formulary
|
Temporary change in RAG status to red due to manufacturing supply issues (Oct 2018)
Potency: moderate
££ Unlicensed
|
|
|
|
|
|
|
| 13.04 |
Topical corticosteriod preparation potencies |
|
|
| 13.05 |
Preparations for eczema and psoriasis |
|
|
|
|
| 13.05.01 |
Preparations for eczema |
|
|
Alitretinoin (Toctino®)
|
Formulary
|
Dermatologists only in line with NICE TA 177
|
NICE TA177: Alitretinoin for the treatment of severe chronic hand eczema
|
|
|
| 13.05.02 |
Preparations for psoriasis |
|
|
Brodalumab (Kyntheum®)
|
Formulary
|
- Hospital only
- In line with NICE
|
NICE TA 511: Brodalumab for treating moderate to severe plaque psoriasis
|
Methoxypsoralen
|
Formulary
|
|
|
|
Risankizumab
|
Formulary
|
Use in line with NICE
|
NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis
|
| 13.05.02 |
Topical preparations for psoriasis |
|
|
Calcipotriol 50mcg/g ointment
|
Formulary
|
|
|
|
Calcipotriol 50mcg/ml scalp application
|
Formulary
|
££££
|
|
|
Calcipotriol 50micrograms/g with Betamethasone 0.05% (Dovobet Gel®)
|
Formulary
|
Scalp psoriasis: usual duration of treatment is 4 weeks
Mild to moderate plaque psoriasis, apply once daily to max. 30% of body surface (max. 15 g daily) for 8 weeks
|
|
|
Calcipotriol 50micrograms/g with Betamethasone 0.05% (Dovobet ointment ®)
|
Formulary
|
4 weeks therapy then assess
Maximum 15g per day or 100g per week.
Step down to calcipotrol oint as per NICE CG153
|
|
|
Calcipotriol 50micrograms/g with Betamethasone 0.05mg/g (Enstilar®)
|
Formulary
|
Cutaneous foam formulation
The recommended treatment period is 4 weeks
Maximum 15g per day
Excipients include liquid paraffin and butane- Extremely flammable aerosol
|
|
|
Calcitriol 3micrograms/g (Silkis®)
|
Formulary
|
Specialist recommendation
For delicate areas,face and flexures
|
|
|
Coal tar lotion 5% (Exorex®)
|
Formulary
|
|
|
|
Coal Tar Solution 2.5%, Arachis (peanut) Oil extract of Coal Tar 7.5%, Tar 7.5%, Cade Oil 7.5%, Liqiud Paraffin 35% (Polytar Emollient®)
|
Formulary
|
contains peanut oil
|
|
|
Dithranol (Dithrocream®)
|
Formulary
|
All Strengths. Specialist Recommendation
|
|
|
Sebco®
|
Formulary
|
|
|
|
Tars - bath preparations (Psoriderm emulsion®)
|
Formulary
|
|
|
|
| 13.05.02 |
Oral retinoids for psoriasis |
|
|
Acitretin
|
Formulary
|
|
|
|
| 13.05.03 |
Drugs affecting the immune response |
|
|
Adalimumab
|
Formulary
|
|
NICE TA146: Adalimumab for the treatment of adults with psoriasis
|
Apremilast
|
Formulary
|
In line with NICE
Use in adults is commissioned by CCGs
|
NICE TA433: Apremilast for treating active psoriatic arthritis
NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
|
Azathioprine (dermatology)
|
Formulary
|
- supported by ESCA, see link below
|
ESCA Azathioprine (dermatology)
UKMI Q&A: Can mothers breastfeed while taking azathioprine?
|
Ciclosporin
|
Formulary
|
- supported by ESCA, see link below
|
ESCA ciclosporin (dermatology)
|
Dimethyl fumarate (Skilarence®)
|
Formulary
|
For use in moderate to severe plaque psoriasis- CCG commissioned
In line with NICE
|
NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
|
Etanercept
|
Formulary
|
use in line with NICE TA 103
|
NICE TA103: Etanercept and efalizumab for the treatment of adults with psoriasis
|
Guselkumab (Tremfya ® )
|
Formulary
|
Use in line with NICE
|
NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis
|
Hydroxycarbamide
|
Formulary
|
|
|
|
Hydroxychloroquine
|
Formulary
|
|
|
|
Infliximab
|
Formulary
|
For treatment of adults with psoriasis- use in line with NICE TA134
|
NICE TA134: Infliximab for psoriasis
|
Ixekizumab (Taltz®)
|
Formulary
|
|
NICE TA 537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis
|
Methotrexate
|
Formulary
|
supported by ESCA (to be developed)
|
UKMI Q&A: What is the clinical significance of the interaction between methotrexate and penicillins? (Oct13)
|
Mycophenolate
|
Formulary
|
supported by ESCA (to be developed)
|
|
|
Omalizumab
|
Formulary
|
In line with NICE
|
NICE TA 339: Omalizumab for previously treated chronic spontaneous urticaria
|
Pimecrolimus (Elidel®)
|
Formulary
|
in line with NICE
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
|
Secukinumab
(![]())
|
Formulary
|
Use in line with NICE
|
TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
TA350: Secukinumab for treating moderate to severe plaque psoriasis
TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
|
Tacrolimus (Protopic®)
|
Formulary
|
in line with NICE
0.03% & 0.1% ointment
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
|
Thalidomide
|
Formulary
|
NHS England commissioned drug
|
|
|
Tildrakizumab
|
Formulary
|
|
NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis
|
Ustekinumab
|
Formulary
|
For treating moderate to severe psoriasis- use in line with NICE TA180
|
NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis
For use in psoriatic arthritis, click here for Chapter 10
|
|
|
|
|
|
|
| 13.06.01 |
Topical preparations for acne |
|
|
| 13.06.01 |
Benzoyl peroxide and azelaic acid |
|
|
Azelaic Acid 15% gel (Finacea®)
|
Formulary
|
|
|
|
Azelaic Acid 20% cream (Skinoren®)
|
Formulary
|
|
|
|
Benzoyl Peroxide
|
Formulary
|
|
|
|
Benzoyl Peroxide 3% with Clindamycin 1% (Duac® Once Daily)
|
Formulary
|
|
|
|
Benzoyl Peroxide 5% with Clindamycin 1% (Duac® Once Daily)
|
Formulary
|
|
|
|
| 13.06.01 |
Topical antibacterials for acne |
|
|
Clindamycin 1% topical solution (Dalacin T ®)
|
Formulary
|
|
|
|
Clindamycin 1% gel (Zindaclin®)
|
Formulary
|
Approved on formulary April 2018
To be reviewed in 12 months to assess clindamycin 1% solution supply issues.
|
|
|
| 13.06.01 |
Topical retinoids and related preparations for acne |
|
|
Adapalene with benzoyl peroxide (Epiduo®)
|
First Choice
|
May be used in preference to antimicrobial-containing agents.
|
|
|
Adapalene
|
Formulary
|
Avoid in pregnancy
|
|
|
| 13.06.01 |
Other topical preparations for acne |
|
|
Nicotinamide 4% gel
|
Formulary
|
3rd Line
|
|
|
| 13.06.02 |
Oral preparations for acne |
|
|
| 13.06.02 |
Oral antibiotics for acne |
|
|
Doxycycline
|
Formulary
|
Topical treatments should be used first line.
Oral antibiotics should be reserved for acne, if topical treatment is not adequately effective or if it is inappropriate.
Please refer to Antimicrobial guidelines
|
|
|
Lymecycline
|
Formulary
|
Topical treatments should be used first line.
Oral antibiotics should be reserved for acne, if topical treatment is not adequately effective or if it is inappropriate.
Please refer to Antimicrobial guidelines
|
|
|
Oxytetracycline
|
Formulary
|
Topical treatments should be used first line.
Oral antibiotics should be reserved for acne, if topical treatment is not adequately effective or if it is inappropriate.
Please refer to Antimicrobial guidelines
|
|
|
Clindamycin
|
Formulary
|
Specialist initiation
12 week course
|
|
|
Rifampicin
|
Formulary
|
Specialist initiation
|
|
|
Trimethoprim
|
Formulary
|
Off label use- Specialist initiation
|
|
|
| 13.06.02 |
Hormone treatment for acne |
|
|
Co-Cyprindiol 2000/35
|
Formulary
|
Prescribe as generic
|
|
|
| 13.06.02 |
Oral retinoid for acne |
|
|
Isotretinoin
|
Formulary
|
Dermatologists only.
Contraindicated in Pregnancy.
|
|
|
| 13.06.03 |
Topical preparations for rosacea |
|
|
Ivermectin 1% cream (Soolantra®)
|
Formulary
|
For topical treatment of inflammatory lesions of rosacea (papulopustular) in adults.
Alternative treatment option to metronidazole 0.75% cream/gel (see section 13.10.1.2) or azelaic acid 15% gel (see section 13.6.1)
|
|
|
| 13.06.03 |
Brimonidine Tartrate |
|
|
Brimonidine tartrate gel (Mirvaso®)
(3mg/g)
|
Formulary
|
For facial erythema in rosacea
|
|
|
| 13.07 |
Preparations for warts and calluses |
|
|
Bleomycin
(intra-lesional)
|
Formulary
|
|
|
|
Glutaraldehyde 10% solution
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL CCG: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Salicylic Acid (Salatac®)
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL CCG: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Salicylic Acid 16.7% with Lactic Acid 16.7% (Salactol®)
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL CCG: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Salicylic Acid Ointment (Verrugon®)
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL CCG: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Silver Nitrate 95% with Potassium Nitrate 5% (AVOCA®)
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL CCG: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Silver Nitrate applicators ( 40% ,75% and 95%)
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL CCG: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Silver Nitrate caustic applicator
|
Formulary
|
|
|
|
| 13.07 |
Anogenital warts |
|
|
Imiquimod 5% (Aldara®)
|
Formulary
|
|
|
|
Podophyllotoxin (Condyline®)
|
Formulary
|
|
|
|
Podophyllotoxin (Warticon®)
|
Formulary
|
|
|
|
Podophyllum
|
Formulary
|
|
|
|
| 13.08 |
Sunscreens and camouflagers |
|
|
| 13.08.01 |
Sunscreen preparations |
|
|
Anthelios XL®
|
Formulary
|
- Approved at December 2015 APC meeting following a drug application.
Non-formulary if not for ACBS approved indication
|
APC decision support tool
|
Sunsense® Ultra
(Lotion, SPF 50)
|
Formulary
|
Non-formulary if not for ACBS approved indication
|
|
|
|
|
Diclofenac sodium 3% gel
|
Formulary
|
££
|
|
|
Fluorouracil (Efudix®)
|
Formulary
|
|
|
|
fluorouracil 0.5%, salicylic acid 10% (Actikerall®)
|
Formulary
|
For hyperkeratotic lesions
|
|
|
Imiquimod 3.75% (Zyclara®)
|
Formulary
|
£££
For field changes >25cm2
|
|
|
Imiquimod 5% (Aldara®)
|
Formulary
|
|
|
|
Ingenol mebutate (Picato®)
|
Formulary
|
£
|
APC decision support tool
FDA Drug Safety Communication: FDA warns of severe adverse events with application of Picato (ingenol mebutate) gel for skin condition; requires label changes
|
Methyl-5-Aminolevulinate (Metvix®)
|
Formulary
|
|
|
|
|
|
Dermacolor®
(camouflage cream, fixing powder)
|
Formulary
|
First line
Specialist recommendation
100 shades available
FP10 prescriptions should be endorsed "ACBS"
|
|
|
Dermablend®
|
Formulary
|
Specialist recommendation
|
|
|
Keromask®
(Masking cream, finishing powder)
|
Formulary
|
Specialist recommendation
FP10 prescriptions should be endorsed "ACBS"
|
|
|
| 13.09 |
Shampoos and other preparations for scalp and hair conditions |
|
|
Capasal®
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL CCG: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Coal Tar Extract 5% (Alcoholic) (Alphosyl 2 in 1®)
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL CCG: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Ketoconazole 2% shampoo
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL CCG: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Polytar Plus®
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL CCG: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Polytar®
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL CCG: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Selenium Sulphide (Selsun®)
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL CCG: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
|
|
| 13.09 |
Androgenetic alopecia |
|
|
Finasteride (Propecia®)
(1mg tablets)
|
 Restricted
|
for hyperandrogenism in women (unlicensed)
Black listed in NHS primary care
 Not NHS
|
|
|
| 13.10 |
Anti-infective skin preparations |
|
|
| 13.10.01 |
Antibacterial preparations |
|
|
| 13.10.01.01 |
Antibacterial preparations only used topically |
|
|
Mupirocin 2%
(cream and ointment)
|
Formulary
|
Please refer to Primary care antimicrobial guidelines
|
Primary Care antimicrobial guidelines
|
Silver Sulfadiazine (Flamazine®)
|
Formulary
|
For infected burns
|
|
|
| 13.10.01.02 |
Antibacterial preparations also used systemically |
|
|
Fusidic Acid 2%
(cream and ointment)
|
Formulary
|
|
|
|
Metronidazole 0.75% (Acea®)
|
Formulary
|
For acne rosacea
|
|
|
Metronidazole 0.75% (Rozex®)
|
Formulary
|
For acne rosacea
|
|
|
Metronidazole 0.75% (Anabact®)
|
Formulary
|
for wounds
|
|
|
| 13.10.02 |
Antifungal preparations |
|
|
Amorolfine 5% nail lacquer
|
Formulary
|
££
|
|
|
Clotrimazole 1%
|
Formulary
|
cream
powder
solution
|
|
|
Ketoconazole 2%
(cream)
|
Formulary
|
££
|
|
|
Miconazole 2%
(cream, dusting powder)
|
Formulary
|
|
|
|
Terbinafine 1% cream
|
Formulary
|
First line for dermatophyte skin infection
|
|
|
| 13.10.03 |
Antiviral preparations |
|
|
Aciclovir 5% cream
|
Formulary
|
|
|
|
| 13.10.04 |
Parasiticidal preparations |
|
|
| 13.10.04 |
Scabies |
|
|
|
|
|
|
|
|
| 13.10.04 |
Benzyl benzonate |
|
|
|
|
| 13.10.04 |
Dimeticone |
|
|
Dimeticone
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL CCG: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
|
|
Malathion
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL CCG: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
|
|
Permethrin 5% (Lyclear® Dermal Cream)
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL CCG: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
|
|
| 13.10.05 |
Preparations for minor cuts and abrasions |
|
|
Magnesium Sulphate Paste BP
|
Formulary
|
Over the counter preparation suitable for self-care/purchase if appropriate
|
BSOL CCG: Conditions for which over the counter items (OTC) should not routinely be prescribed in primary care
Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs
|
Proflavine Cream, BPC
|
Restricted
|
Hospital only
|
|
|
| 13.10.05 |
Collodion |
|
|
| 13.10.05 |
Skin tissue adhesive |
|
|
Dermabond ProPen®
|
Restricted
|
Hospital only
|
|
|
Histoacryl®
|
Restricted
|
Hospital only
|
|
|
Indermil®
|
Restricted
|
Hospital only
|
|
|
| 13.11 |
Skin cleansers, antiseptics, and desloughing agents |
|
|
| 13.11.01 |
Alcohols and saline |
|
|
Sodium Chloride 0.9% irrigation sachets
|
Formulary
|
|
|
|
| 13.11.02 |
Chlorhexidine salts |
|
|
Chlorhexidine acetate 0.015% with cetrimide 0.15% (Travasept 100®)
|
Formulary
|
|
|
|
Chlorhexidine gluconate preparations
|
Formulary
|
|
|
|
Hibitane Obstetric®
|
Formulary
|
|
|
|
Octenisan® antimicrobial wash lotion
|
Formulary
|
MRSA skin decolonisation, if chlorhexidine sensitivity is a problem
|
|
|
| 13.11.04 |
Iodine and Chlorine |
|
|
Povidone-Iodine preparations
|
Formulary
|
|
|
|
|
|
| 13.11.06 |
Oxidisers, and dyes |
|
|
Hydrogen Peroxide (Crystacide®)
|
Formulary
|
|
|
|
Hydrogen Peroxide 3% Solution (10vols)
|
Formulary
|
|
|
|
Hydrogen Peroxide 6% Solution (20vols)
|
Formulary
|
|
|
|
Potassium Permanganate tablets
|
Formulary
|
|
|
|
| 13.11.07 |
Desloughing agents |
|
|
|
|
| 13.12 |
Antiperspirants |
|
|
Aluminimum Salts
|
Formulary
|
|
|
|
Oxybutynin immediate release tablets
|
Formulary
|
For hyperhidrosis (off label use)
after trial of aluminium salts
|
|
|
Propantheline
|
Formulary
|
For hyperhidrosis (licensed indication)
Specialist recommendation
|
|
|
Botulinum toxin type A
|
Formulary
|
hyperhidrosis (commissioning discussion to take place)
|
|
|
Glycopyrronium
|
Formulary
|
- Unlicensed
- For specialist initiation for hyperhidrosis
- ££££
|
|
|
| 13.13 |
Topical circulatory preparations |
|
|
Heparinoid 0.3% (Hirudoid®)
|
Formulary
|
|
|
|
| 13.14 |
Dermatology Specials |
|
|
|
| 13.14.01 |
Emollients and barriers |
|
|
Propylene glycol 20% w/w in aqueous cream
|
Formulary
|
|
|
|
| 13.14.02 |
Steroid combinations |
|
|
Salicylic acid 5% w/w / propylene glycol 47.5% w/w in Dermovate® cream
|
Formulary
|
|
|
|
Propylene glycol 40% w/w in Dermovate® cream
|
Formulary
|
|
|
|
Coal tar solution BP 5% w/w in betamethasone valerate 0.025% w/w ointment
|
Formulary
|
|
|
|
Coal tar solution BP 3.3% w/w and propylene glycol 20% w/w in Synalar® gel
|
Formulary
|
|
|
|
| 13.14.03 |
Tars |
|
|
Cade oil 12% w/w and salicylic acid 6% w/w in emulsifying ointment
|
Formulary
|
|
|
|
coal tar solution BP 6% w/w / salicylic acid 2% w/w in emulsifying ointment
(Coal tar scalp pomade)
|
Formulary
|
|
|
|
Coal tar BP 2% w/w in YSP
|
Formulary
|
|
|
|
Coal tar BP 5% w/w in YSP
|
Formulary
|
|
|
|
Coal tar BP 10% w/w in YSP
|
Formulary
|
|
|
|
Coal tar solution BP 6% w/w and salicylic acid 6% w/w in Ung. merck
|
Formulary
|
|
|
|
|
|
Ichthammol 1% w/w and zinc oxide 15% w/w in YSP
|
Formulary
|
|
|
|
| 13.14.05 |
Dithranol preparations |
|
|
Dithranol in Lassar’s paste 0.1% w/w
|
Formulary
|
|
|
|
Dithranol in Lassar’s paste 0.5% w/w
|
Formulary
|
|
|
|
Dithranol in Lassar’s paste 1% w/w
|
Formulary
|
|
|
|
Dithranol in Lassar’s paste 2% w/w
|
Formulary
|
|
|
|
Dithranol in Lassar’s paste 4% w/w
|
Formulary
|
|
|
|
Dithranol in Lassar’s paste 8% w/w
|
Formulary
|
|
|
|
Dithranol in Lassar’s paste 10% w/w
|
Formulary
|
|
|
|
Dithranol in Lassar’s paste 15% w/w
|
Formulary
|
|
|
|
Dithranol pomade 0.4% w/w
|
Formulary
|
dithranol 0.4% w/w, salicylic acid 2% w/w, emulsifying wax BP 25% w/w, liquid paraffin to 100%
|
|
|
|
|
Coconut oil 25% w/w in emulsifying ointment
|
Formulary
|
|
|
|
Salicylic acid 2% w/w and sulphur 2% w/w in aqueous cream
|
Formulary
|
|
|
|
Salicylic acid 2% w/w in emulsifying ointment
|
Formulary
|
|
|
|
Salicylic acid 5% w/w in emulsifying ointment
|
Formulary
|
|
|
|
Salicylic acid 10% w/w in emulsifying ointment
|
Formulary
|
|
|
|
Salicylic acid 20% w/w in emulsifying ointment
|
Formulary
|
|
|
|
Zinc and salicylic acid paste (Lassar’s paste) half-strength
|
Formulary
|
|
|
|
|
|
Diphenylcyclopropenone in acetone 0.00001-6.0% w/v
|
Formulary
|
|
|
|
Eosin solution 2% w/v
|
Formulary
|
|
|
|
Glycopyrrolate 0.05% w/v in water
|
Formulary
|
|
|
|
Glycopyrrolate 2% w/w in cetomacrogol cream
|
Formulary
|
|
|
|
Hydroquinone 5% w/w, hydrocortisone 1% w/w and tretinoin 0.1% (w/w in a non-aqueous gel 0.3% w/v)
|
Formulary
|
|
|
|
Phenol 2% w/w in compound zinc paste BP
|
Formulary
|
|
|
|
Reflectant (Dundee) sunscreens
|
Formulary
|
coffee, coral pink, beige
|
|
|
Tacrolimus 0.1% w/w in OrabaseTM
|
Formulary
|
|
|
|
Tacrolimus 0.3% w/w in OrabaseTM
|
Formulary
|
|
|
|
Triamcinolone acetonide 0.1% w/w in OrabaseTM
|
Formulary
|
|
|
|
Trichloroacetic acid 90% w/v
|
Formulary
|
|
|
|
| 13.15 |
Miscellaneous |
|
|
Mepacrine Hydrochloride
|
Formulary
|
For Discoid lupus erythematosus (DLE)
|
See Chapter 5
|
| .... |
| Non Formulary Items |
Aveeno®Bath Additive
|
Non Formulary
|
|
|
|
Abrasive Agents (Brasivol®)
|
Non Formulary
|
|
|
|
Alclometasone Dipopionate (Modrasone®)
|
Non Formulary
|
|
|
|
Alcohol
|
Non Formulary
|
|
|
|
Aminolevulinic acid
|
Non Formulary
|
|
|
|
Antibacterials (Stiemycin®)
|
Non Formulary
|
|
|
|
Aqueous Cream BP
|
Non Formulary
|
|
|
|
Bacaplermin (Regranex®)
|
Non Formulary
|
|
|
|
Barrier preparation (Drapolene®)
|
Non Formulary
|
|
|
|
Barrier preparation (Medicaid®)
|
Non Formulary
|
|
|
|
Barrier preparation (Morhulin®)
|
Non Formulary
|
|
|
|
Barrier preparation (Silicone barrier cream)
|
Non Formulary
|
|
|
|
Barrier preparation (Vasogen®)
|
Non Formulary
|
|
|
|
Beclomethasone diproprionate
|
Non Formulary
|
cream, ointment and scalp application |
|
|
Benzoic Acid
|
Non Formulary
|
|
|
|
Benzoyl Peroxide with antimcrobials (Quinoderm®)
|
Non Formulary
|
|
|
|
Benzyl Benzoate Application BP 25%
|
Non Formulary
|
|
|
|
Betamethasone (as Dipropionate) 0.05% (Diprosone®)
|
Non Formulary
|
|
|
|
Betamethasone (as Valerate) 0.1% with Clioquinol
|
Non Formulary
|
|
|
|
Betamethasone (as Valerate) 0.1% with Neomycin Sulphate 0.5% (Betnovate-N®)
|
Non Formulary
|
|
|
|
Betamethasone Esters (Betacap®)
|
Non Formulary
|
|
|
|
Betamethasone Esters (Betesil®)
|
Non Formulary
|
|
|
|
Betamethasone Esters (Bettamousse®)
|
Non Formulary
|
|
|
|
Borderline Substances (Delph®)
|
Non Formulary
|
|
|
|
Borderline Substances (SpectraBan®)
|
Non Formulary
|
|
|
|
Carbaryl (Carylderm®)
|
Non Formulary
|
discontinued |
|
|
Cetraben®Bath additive
|
Non Formulary
|
|
|
|
Cidofovir in Unguentum M
|
Non Formulary
|
|
|
|
Clobetasol propionate (Clarelux®)
|
Non Formulary
|
|
|
|
Clobetasol Propionate with neomycin and nystatin (Dermovate-NN®)
|
Non Formulary
|
|
|
|
Coal Tar 10% (Carbo-Dome®)
|
Non Formulary
|
|
|
|
Coal Tar in Lassars Paste
|
Non Formulary
|
|
|
|
Coal Tar in Unguentum M
|
Non Formulary
|
|
|
|
Coconut, anise, and ylang ylang spray (Lyclear SprayAway)
|
Non Formulary
|
|
|
|
Collodion Flexible BP
|
Non Formulary
|
|
|
|
Corticosteroids (Actinac®)
|
Non Formulary
|
|
|
|
Covermark®
|
Non Formulary
|
|
|
|
Crystal violet
|
Non Formulary
|
Update following APC harmonisation |
|
|
Cyclomethicone 50% / Isopropyl myristate 50% solution (Full Marks solution)
|
Non Formulary
|
|
|
|
Diprobase®
|
Non Formulary
|
|
|
|
Dithranol (Micanol®)
|
Non Formulary
|
|
|
|
Dithranol (Psorin®)
|
Non Formulary
|
|
|
|
Dithranol Ointment BP
|
Non Formulary
|
|
|
|
Dithranol Paste BP
|
Non Formulary
|
|
|
|
Dundee reflective sun creams (Dundee Block®)
|
Non Formulary
|
|
|
|
E45®
|
Non Formulary
|
|
|
|
Econazole (Pevaryl®)
|
Non Formulary
|
|
|
|
Econazole Nitrate (Ecostatin®)
|
Non Formulary
|
|
|
|
Econazole Nitrate (Pevaryl®)
|
Non Formulary
|
|
|
|
Efalizumab (Raptiva®)
|
Non Formulary
|
|
|
|
Eflornithine (Vaniqa®)
|
Non Formulary
|
|
|
|
Emollient Bath Additive (Alpha Keri Bath®)
|
Non Formulary
|
|
|
|
Emollient Bath Additive (Dermalo®)
|
Non Formulary
|
|
|
|
Emollient Bath Additive (Diprobath®)
|
Non Formulary
|
|
|
|
Emollient Bath Additive (E45®)
|
Non Formulary
|
|
|
|
Emollient Bath Additive (Imuderm®)
|
Non Formulary
|
|
|
|
Emollient Bath Additive (QV®)
|
Non Formulary
|
|
|
|
Emollient Bath Additive (Zerolatum®)
|
Non Formulary
|
|
|
|
Emollient Bath Additive with Anitmicrobials (Emulsiderm®)
|
Non Formulary
|
|
|
|
Emollient Bath Additives (Zeroneum®)
|
Non Formulary
|
|
|
|
Emollient Bath Additives (Zerozole®)
|
Non Formulary
|
|
|
|
Emollient preparation (Decubal® Clinic)
|
Non Formulary
|
|
|
|
Emollient preparation (Dermamist®)
|
Non Formulary
|
|
|
|
Emollient preparation (Drapolene®)
|
Non Formulary
|
|
|
|
Emollient preparation (Hewletts®)
|
Non Formulary
|
|
|
|
Emollient preparation (Kamillosan®)
|
Non Formulary
|
|
|
|
Emollient preparation (Keri®)
|
Non Formulary
|
|
|
|
Emollient preparation (Linola® Gamma)
|
Non Formulary
|
|
|
|
Emollient preparation (Lipobase®)
|
Non Formulary
|
|
|
|
Emollient preparation (Neutogena® Dermatological Cream)
|
Non Formulary
|
|
|
|
Emollient preparation (Ultrabase®)
|
Non Formulary
|
|
|
|
Emollient preparation (Vaseline Dermacare®)
|
Non Formulary
|
|
|
|
Emollient preparation containing Urea (Calmurid®)
|
Non Formulary
|
|
|
|
Emollient preparation containing Urea (E45® Itch Releif Cream)
|
Non Formulary
|
|
|
|
Emollient preparation containing Urea (Nutraplus®)
|
Non Formulary
|
|
|
|
Emollient preparation with antimicrobials (Eczmol®)
|
Non Formulary
|
|
|
|
Emollient preparation with antimicrobials (Zerolatum® Plus)
|
Non Formulary
|
|
|
|
Emollin®
(Spray)
|
Non Formulary
|
New application NOT approved Oct 2017 |
|
|
Erythromycin
|
Non Formulary
|
|
|
|
Erythromycin 40mg with Zinc Acetate 12mg/mL (Zineryt®)
|
Non Formulary
|
|
|
|
Flexitol®
|
Non Formulary
|
|
|
|
Flucinolone Acetonide 0.00625% (Synalar 1 in 4 Dilution®)
|
Non Formulary
|
|
|
|
Flucinolone Acetonide 0.025% (Synalar cream®)
|
Non Formulary
|
|
|
|
Flucinolone Acetonide 0.025% with Neomycin Sulphate 0.5% (Synalar N®)
|
Non Formulary
|
|
|
|
Flucinonide 0.05% (Metosyn®)
|
Non Formulary
|
|
|
|
Flucortolone (Ultralanum Plain®)
|
Non Formulary
|
|
|
|
Fluticasone Propionate (Cutivate®)
|
Non Formulary
|
|
|
|
Formaldehyde 10% solution
|
Non Formulary
|
|
|
|
Fumaderm®
|
Non Formulary
|
Non-formulary November 2018 |
|
|
Griseofulvin (Grisol AF®)
|
Non Formulary
|
|
|
|
Hydrocortisone (Hydromol® HC Intensive)
|
Non Formulary
|
|
|
|
Hydrocortisone 1% with Urea 10% (Alphderm®)
|
Non Formulary
|
|
|
|
Hydrocortisone 1%, Clioquinol 3% (Vioform-Hydrocortisone Cream®)
|
Non Formulary
|
Discontinued Dec 2014 |
|
|
Hydrocortisone 1%, Urea 10% and Lactic Acid 5% (Calmurid HC®)
|
Non Formulary
|
|
|
|
Hydrocortisone Butyrate (Locoid Crelo®)
|
Non Formulary
|
|
|
|
Hydrocortisone Butyrate 0.1% with Chlorquinaldol 3% (Locoid C®)
|
Non Formulary
|
|
|
|
Hydrocortisone with antimicrobials (Econacort®)
|
Non Formulary
|
|
|
|
Hydromol® Intensive
|
Non Formulary
|
|
|
|
Ichthammol
|
Non Formulary
|
|
|
|
Ichthammol 1% w/w paste
|
Non Formulary
|
|
|
|
Idoxuridine in Dimethyl Sulfoxide (Herpid®)
|
Non Formulary
|
|
|
|
Industrial Methylated Spirit BP
|
Non Formulary
|
|
|
|
Isotretinoin 0.05% gel
|
Non Formulary
|
Avoid in pregnancy
Discontinued. Manufacturer confirmed in April 2017 that production has ceased and that no new batches will be manufactured or shipped. |
|
|
Isotretinoin with antibacterial (Isotrexin®)
|
Non Formulary
|
|
|
|
Lanolin emollient spray
|
Non Formulary
|
|
|
|
LiquiBand®
|
Non Formulary
|
|
|
|
Metronidazole (Metrogel®)
|
Non Formulary
|
|
|
|
Metronidazole (Metrosa®)
|
Non Formulary
|
|
|
|
Metronidazole (Metrotop®)
|
Non Formulary
|
Discontinued |
|
|
Metronidazole (Noritate®)
|
Non Formulary
|
|
|
|
Metronidazole (Zyomet®)
|
Non Formulary
|
|
|
|
Minoxidil (Regaine®)
|
Non Formulary
|
|
|
|
Neomycin Sulphate 0.5%
|
Non Formulary
|
|
|
|
Nystatin
|
Non Formulary
|
|
|
|
Nystatin (Tinaderm-M®)
|
Non Formulary
|
|
|
|
Nystatin 100,000 uints/g (Nystan®)
|
Non Formulary
|
|
|
|
Nystatin with Chlorhexidine cream (Nystaform®)
|
Non Formulary
|
|
|
|
Oilatum®
|
Non Formulary
|
|
|
|
Oilatum® Plus (emollient bath additive)
|
Non Formulary
|
|
|
|
Oilatum® shower emollient gel
|
Non Formulary
|
|
|
|
Oilatum®Emollient
|
Non Formulary
|
|
|
|
Other scalp preparations (Cocois®)
|
Non Formulary
|
|
|
|
Penciclovir (Vectavir®)
|
Non Formulary
|
|
|
|
Permethrin 1% (Lyclear® Creme Rinse)
|
Non Formulary
|
|
|
|
Phenothrin (Full Marks®)
|
Non Formulary
|
|
|
|
Polyfax®
|
Non Formulary
|
Product discontinued November 2017 |
|
|
Potassium hydroxide 5% solution (Molludab®)
|
Non Formulary
|
|
|
|
QV®
|
Non Formulary
|
|
|
|
Salicyic Acid in White Soft Paraffin
|
Non Formulary
|
|
|
|
Salicylic Acid (Acnisal®)
|
Non Formulary
|
|
|
|
Salicylic Acid (Cuplex®)
|
Non Formulary
|
|
|
|
Salicylic Acid (Duofilm®)
|
Non Formulary
|
|
|
|
Salicylic Acid (Occlusal®)
|
Non Formulary
|
|
|
|
Salicylic Acid (Phytex®)
|
Non Formulary
|
|
|
|
Salicylic Acid 3% w/w, Sulphur 3% w/w in Aqueous Cream
|
Non Formulary
|
|
|
|
Salicylic Acid 3% w/w, Sulphur 3% w/w in Aqueous Cream
|
Non Formulary
|
|
|
|
Salicylic Acid in White Soft Paraffin
|
Non Formulary
|
|
|
|
Salicylic Acid in White Soft Paraffin
|
Non Formulary
|
|
|
|
Salicylic Acid with podophyllum (Posalfflin®)
|
Non Formulary
|
|
|
|
Shampoos (Betadine®)
|
Non Formulary
|
|
|
|
Shampoos (Ceanel Concentrate®)
|
Non Formulary
|
|
|
|
Shampoos (Clinitar®)
|
Non Formulary
|
|
|
|
Shampoos (Dermax®)
|
Non Formulary
|
|
|
|
Shampoos (Meted®)
|
Non Formulary
|
|
|
|
Shampoos (Pentrax®)
|
Non Formulary
|
|
|
|
Shampoos (Polytar AF®)
|
Non Formulary
|
|
|
|
Shampoos (Psoriderm®)
|
Non Formulary
|
|
|
|
Shampoos (T/Gel®)
|
Non Formulary
|
|
|
|
Siopel®
|
Non Formulary
|
|
|
|
Skin tissue adhesive (Epiglu®)
|
Non Formulary
|
|
|
|
Sodium Hypochorite Solution 1% (Milton®)
|
Non Formulary
|
|
|
|
Sorbaderm®
|
Non Formulary
|
|
|
|
Sprilon®
|
Non Formulary
|
|
|
|
Sulconazole Nitrate (Exelderm®)
|
Non Formulary
|
|
|
|
Sunscreen (E45 Sun®)
|
Non Formulary
|
|
|
|
Sunscreen (Roc®)
|
Non Formulary
|
|
|
|
Tacalcitol (Curatoderm®)
|
Non Formulary
|
|
|
|
Tars
|
Non Formulary
|
|
|
|
Tars (Clinitar®)
|
Non Formulary
|
|
|
|
Tars (Cocois®)
|
Non Formulary
|
|
|
|
Tars (Psoriderm®)
|
Non Formulary
|
|
|
|
Tars (Zinc and Coal Tar Paste®)
|
Non Formulary
|
|
|
|
Tars - bath preparations
|
Non Formulary
|
|
|
|
Tars - bath preparations (Pinetarsol®)
|
Non Formulary
|
|
|
|
Tazarotene 0.05% (Zorac®)
|
Non Formulary
|
|
|
|
Tioconazole (Trosyl®)
|
Non Formulary
|
|
|
|
Tretinoin with antibacterial (Aknemycin® Plus)
|
Non Formulary
|
|
|
|
Tri-Adcortyl®
|
Non Formulary
|
|
|
|
Triamcinolone Acetonide 0.1% with Chlortetracycline Hydrochloride 3% (Aureocort®)
|
Non Formulary
|
Discontinued Feb 2017 |
|
|
Trichloroacetic Acid
|
Non Formulary
|
|
|
|
Triclosan (Manusept®)
|
Non Formulary
|
|
|
|
Triclosan 1% (Skinsan®)
|
Non Formulary
|
|
|
|
Triclosan 2% (Aquasept®)
|
Non Formulary
|
Discontinued |
|
|
Triclosan 2% (Ster-Zac Bath Concentrate®)
|
Non Formulary
|
|
|
|
Undecenoates (Monphytol®)
|
Non Formulary
|
|
|
|
Undecenoates (Mycota®)
|
Non Formulary
|
|
|
|
Unguentum M®
|
Non Formulary
|
|
|
|
Urea 5% Special Preparation
|
Non Formulary
|
|
|
|
Uvistat®
|
Non Formulary
|
|
|
|
Veil®
|
Non Formulary
|
|
|
|
Yellow Soft Parrafin BP
|
Non Formulary
|
|
|
|
Zinc and Salicylic Acid Paste BP
|
Non Formulary
|
|
|
|
Zinc Cream BP
|
Non Formulary
|
|
|
|
Zinc Ointment BP
|
Non Formulary
|
|
|
|
| |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Prescribing in children
The APC notes that the informed use of unlicensed medicines or of licensed medicines for unlicensed applications (‘off-label’ use) is often necessary in paediatric practice.
The APC advises GPs to consider specialist prescribing recommendations for Green and Amber medicines that are not subject to ESCAs or RICaDs in combination with the information provided in the BNFC which goes beyond that of marketing authorisations. The BNFC has been designed for rapid reference and the information presented has been carefully selected to aid decisions on prescribing.
|
|
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications. |
|
Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate, or initiation and maintenance of prescribing in Primary Care following recommendation from a Specialist.
Some amber medicines require agreement with the local (internal) medicines committee prior to initiation; others may require a framework to support safe transfer and maintenance of care such as a RICaD or ESCA. The Formulary will be annotated to reflect these requirements. |
|
Medicines for initiation and maintenance prescribing by Specialists only |
|
Non-formulary medicines- medicines not recommended for routine primary care prescribing. |
|
Positive NICE TA and /or awaiting local clarification on place in therapy ; Please contact your Medicines Optimisation team for more information. |
|
|
|
